HTTIF (HighTide Therapeutics) General and Admin. Expense: $8.33 Mil (TTM As of Dec. 2025)


HTTIF HighTide Therapeutics Inc HTTIF
14 GF Score
Price $0.35
! 3 Warning Signs
View Full Analysis

What is HighTide Therapeutics General and Admin. Expense?

HighTide Therapeutics HTTIF 14 General and Admin. Expense is $8.33 Mil as of Dec. 2025. GuruFocus rates HTTIF with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. HighTide Therapeutics's General and Admin. Expense for the six months ended in Dec. 2025 was $5.32 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 was $8.33 Mil.

HighTide Therapeutics General and Admin. Expense Related Terms

HighTide Therapeutics General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for HighTide Therapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HighTide Therapeutics General and Admin. Expense Chart

HighTide Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
6.42 6.23 19.14 11.16 8.39

HighTide Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only 11.86 6.35 4.83 3.01 5.32
HTTIF
14GF Score
HighTide Therapeutics Inc HTTIF
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HighTide Therapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $8.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of $8.33 Mil mean?
HighTide Therapeutics (HTTIF) has a General and Admin. Expense of $8.33 Mil as of Dec. 2025. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on HighTide Therapeutics and its competitors.
Is HighTide Therapeutics' General and Admin. Expense too high?
HighTide Therapeutics' current General and Admin. Expense is $8.33 Mil. Overall, HighTide Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does HighTide Therapeutics' General and Admin. Expense compare to VRTX and REGN?
HighTide Therapeutics' General and Admin. Expense of $8.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on HighTide Therapeutics and its competitors. HighTide Therapeutics's current General and Admin. Expense is $8.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HighTide Therapeutics stock overvalued right now?
HighTide Therapeutics (HTTIF) has a current General and Admin. Expense of $8.33 Mil. The current General and Admin. Expense is $8.33 Mil. HighTide Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For HighTide Therapeutics (HTTIF), the current General and Admin. Expense is $8.33 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HighTide Therapeutics Business Description

Other Exchanges 02511:Hong Kong
Address Fubao Street, 9th to 10th Floor, Building D, Shenfang Park, Futian District, Shenzhen-Hong Kong Science and, Technology Innovation Cooperation Zone, Guangdong, Shenzhen, CHN, 518112
HighTide Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of first-in-class multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases and related metabolic disorders. The company is developing a pipeline of proprietary drug candidates targeting indications including type 2 diabetes mellitus, chronic kidney disease, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and primary sclerosing cholangitis (PSC). Its core product candidate, HTD1801 (berberine ursodeoxycholate), is an orally delivered first-in-class anti-inflammatory metabolic modulator designed to target dual pathways involving AMPK activation and NLRP3 inflammasome inhibition.
14GF Score

Get the complete analysis for HTTIF

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.35
Price